Athira Pharma, Inc.
ATHA
$0.239
$0.014.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.00% | -3.42% | -41.41% | -23.90% | -9.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.20% | -27.25% | -11.42% | -7.00% | 33.65% |
| Operating Income | 49.20% | 27.25% | 11.42% | 7.00% | -33.65% |
| Income Before Tax | 45.01% | 12.83% | 9.25% | 5.33% | 9.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.01% | 12.83% | 9.25% | 5.33% | 9.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.01% | 12.83% | 9.25% | 5.33% | 9.46% |
| EBIT | 49.20% | 27.25% | 11.42% | 7.00% | -33.65% |
| EBITDA | 49.59% | 27.44% | 11.50% | 7.07% | -33.98% |
| EPS Basic | 45.87% | 13.87% | 10.16% | 6.31% | 10.05% |
| Normalized Basic EPS | 49.32% | 26.24% | 10.15% | 6.47% | -41.56% |
| EPS Diluted | 45.87% | 13.87% | 10.16% | 5.94% | 10.05% |
| Normalized Diluted EPS | 49.32% | 26.24% | 10.15% | 6.47% | -41.56% |
| Average Basic Shares Outstanding | 1.58% | 1.22% | 1.00% | 1.05% | 0.66% |
| Average Diluted Shares Outstanding | 1.58% | 1.22% | 1.00% | 1.05% | 0.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |